Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 388

3.

Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial.

Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, Uleman C.

Liver Transpl. 2004 Oct;10(10):1258-62.

4.

Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients.

Berenguer M, Aguilera V, San Juan F, Benlloch S, Rubin A, López-Andujar R, Moya A, Pareja E, Montalva E, Yago M, de Juan M, Mir J, Prieto M.

Transplantation. 2010 Dec 15;90(11):1204-9. doi: 10.1097/TP.0b013e3181fa93fa.

PMID:
21068701
5.

Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation.

Tamè M, Buonfiglioli F, Del Gaudio M, Lisotti A, Cecinato P, Colecchia A, Azzaroli F, D'Errico A, Arena R, Calvanese C, Quarneti C, Ballardini G, Pinna AD, Mazzella G.

World J Gastroenterol. 2013 Aug 28;19(32):5278-85. doi: 10.3748/wjg.v19.i32.5278.

6.

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.

Curry MP, Forns X, Chung RT, Terrault NA, Brown R Jr, Fenkel JM, Gordon F, O'Leary J, Kuo A, Schiano T, Everson G, Schiff E, Befeler A, Gane E, Saab S, McHutchison JG, Subramanian GM, Symonds WT, Denning J, McNair L, Arterburn S, Svarovskaia E, Moonka D, Afdhal N.

Gastroenterology. 2015 Jan;148(1):100-107.e1. doi: 10.1053/j.gastro.2014.09.023. Epub 2014 Sep 28.

7.

Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine.

Villamil F, Levy G, Grazi GL, Mies S, Samuel D, Sanjuan F, Rossi M, Lake J, Munn S, Mühlbacher F, Leonardi L, Cillo U.

Transplant Proc. 2006 Nov;38(9):2964-7.

PMID:
17112875
8.

Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.

Saab S, Hunt DR, Stone MA, McClune A, Tong MJ.

Liver Transpl. 2010 Jun;16(6):748-59. doi: 10.1002/lt.22072.

9.

Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation.

Zervos XA, Weppler D, Fragulidis GP, Torres MB, Nery JR, Khan MF, Pinna AD, Kato T, Miller J, Reddy KR, Tzakis AG.

Transplantation. 1998 Apr 27;65(8):1044-6.

PMID:
9583863
10.

Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.

Manousou P, Samonakis D, Cholongitas E, Patch D, O'Beirne J, Dhillon AP, Rolles K, McCormick A, Hayes P, Burroughs AK.

Liver Transpl. 2009 Dec;15(12):1783-91. doi: 10.1002/lt.21907.

11.

Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.

Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J.

Liver Transpl. 2006 May;12(5):762-7.

13.

Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.

Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD.

Ann Surg. 2008 Nov;248(5):857-62. doi: 10.1097/SLA.0b013e3181896278.

PMID:
18948815
14.

REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C.

Levy G, Villamil FG, Nevens F, Metselaar HJ, Clavien PA, Klintmalm G, Jones R, Migliaccio M, Prestele H, Orsenigo R; REFINE Study Group.

Am J Transplant. 2014 Mar;14(3):635-46. doi: 10.1111/ajt.12620. Epub 2014 Jan 23.

15.

Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.

Testillano M, Fernandez JR, Suarez MJ, Gastaca M, Bustamante J, Pijoan JI, Montejo M, Valdivieso A, Ruiz P, Gonzalez J, Ortiz de Urbina J.

Transplant Proc. 2009 Apr;41(3):1041-3. doi: 10.1016/j.transproceed.2009.02.030.

PMID:
19376421
16.

University of Modena experience in HIV-positive patients undergoing liver transplantation.

Di Benedetto F, Tarantino G, De Ruvo N, Cautero N, Montalti R, Guerrini GP, Ballarin R, Spaggiari M, Smerieri N, Serra V, Rompianesi G, D'Amico G, Mimmo A, Iemmolo RM, Codeluppi M, Cocchi S, Guaraldi G, Gerunda GE.

Transplant Proc. 2011 May;43(4):1114-8. doi: 10.1016/j.transproceed.2011.03.017.

PMID:
21620066
17.

Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus.

Shindoh J, Hasegawa K, Matsuyama Y, Inoue Y, Ishizawa T, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M, Kokudo N.

J Clin Oncol. 2013 Feb 20;31(6):766-73. doi: 10.1200/JCO.2012.44.3234. Epub 2012 Nov 5.

PMID:
23129744
18.

Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.

Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S.

Transplant Proc. 2011 Apr;43(3):905-8. doi: 10.1016/j.transproceed.2011.02.034.

PMID:
21486625
19.

Recurrence of hepatitis C virus (genotype 4) infection after living-donor liver transplant in Egyptian patients.

Yosry A, Abdel-Rahman M, Esmat G, El-Serafy M, Omar A, Doss W, Zayed N, Said M, Ismail T, Hosny A, Marawan E, El-Malt O, Kamel RR, Hatata Y, El-Taweel A, Ghali A, Sabri H, Kamel S, El-Gabaly H.

Exp Clin Transplant. 2009 Sep;7(3):157-63.

20.

Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy.

Roos K, Gotthardt D, Giese T, Schnitzler P, Stremmel W, Czock D, Eisenbach C.

Liver Transpl. 2014 Sep;20(9):1106-17. doi: 10.1002/lt.23925. Epub 2014 Aug 4.

Supplemental Content

Support Center